GOODWILL AND INTANGIBLE ASSETS, NET - Intangible Assets - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Milestone payment accrued for FDA approval of Vyleesi		$ 60,000	$ 60,000
Goodwill	$ 422,513			$ 422,513	$ 422,513
Impairment of intangible assets	151,300
Impairment of assets	155,000			232,336	0	$ 319,246
Amortization of intangible assets				$ 24,800	158,400	$ 130,400
Expected useful life				1 year
Expect amortization expense related to finite-lived intangible assets during the next 12 months	23,600			$ 23,600
Developed technology rights
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets				7,100
Vyleesi Products | Developed technology rights
Finite-Lived Intangible Assets [Line Items]
Fair value of intangible asset	11,752			11,752	0
Impairment of intangible assets	39,000
Makena auto-injector developed technology | Developed technology rights
Finite-Lived Intangible Assets [Line Items]
Fair value of intangible asset	7,892			7,892	72,148
Impairment of intangible assets	55,400
Makena | Developed technology rights
Finite-Lived Intangible Assets [Line Items]
Fair value of intangible asset	0			0	77,359
Impairment of intangible assets		$ 77,400	$ 77,400
Intrarosa | Developed technology rights
Finite-Lived Intangible Assets [Line Items]
Fair value of intangible asset	3,976			$ 3,976	$ 67,526
Impairment of intangible assets	$ 56,900